Bola Adamolekun, MD
Neurology · Arlington, TNNPI 1104816990
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (39.4%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. 27 manufacturers reported payments, led by Supernus Pharmaceuticals, Inc. at 28.4% of the total. Reporting peaked in 2020 at $7,492 and has fallen 88.9% since, to $835 in 2025.
Across 216 payments — averaging $93.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Supernus Pharmaceuticals, Inc.$6K
- AbbVie$6K
- Merck$3K
- SK Life Science, Inc.$2K
- Livanova USA, Inc.$1K
- Sunovion Pharmaceuticals Inc.$375
- plus $1K from 21 others
Across 7 payments — averaging $12,173 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- UCB SA$85K
What the payments were for
- Consulting fees$5,37527%
- Speaking & faculty fees$7,97539%
- Travel & lodging$2,83714%
- Food & beverage$4,06020%
- Education$140%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Supernus Pharmaceuticals, Inc. | 15 | $5,759 |
| AbbVie(2 entities) | 61 | $5,579 |
| Merck | 5 | $3,450 |
| SK Life Science, Inc. | 22 | $2,243 |
| Livanova USA, Inc. | 8 | $1,414 |
| Sunovion Pharmaceuticals Inc. | 31 | $375 |
| Novartis | 19 | $256 |
| UCB, Inc. | 7 | $227 |
| Eisai Inc. | 9 | $198 |
| AstraZeneca | 5 | $148 |
| Teva Pharmaceuticals USA, Inc. | 8 | $121 |
| Penumbra, Inc. | 1 | $85 |
| Biogen | 4 | $71 |
| Amgen(2 entities) | 3 | $58 |
| EMD Serono, Inc. | 4 | $48 |
| Biohaven Pharmaceuticals, Inc. | 2 | $30 |
| Lilly USA, LLC | 2 | $25 |
| Sanofi | 1 | $23 |
| Boston Scientific | 1 | $22 |
| Abbott | 1 | $19 |
| Arbor Pharmaceuticals, Inc. | 1 | $18 |
| Avanir Pharmaceuticals, Inc. | 1 | $18 |
| Ipsen Biopharmaceuticals, Inc | 1 | $17 |
| Amneal Pharmaceuticals LLC | 1 | $16 |
| CSL Behring | 1 | $15 |
| Tanabe Pharma America, Inc. | 1 | $15 |
| GE HealthCare | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OXTELLAR XR$5,643
- UBRELVY$4,940
- Cenobamate$1,925
- VNS Therapy$1,374
- Briviact$125
- XCOPRI$117
- Fycompa$108
How this compares
$20,261 in reported general payments places this provider in the 80th percentile of 361 neurology providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FycompaPerampanel | 55 | $70,640 |
| Lacosamide | 321 | $49,886 |
| BriviactBrivaracetam | 22 | $49,386 |
| Nurtec OdtRimegepant Sulfate | 25 | $28,171 |
| Levetiracetam | 507 | $26,034 |
| Aimovig AutoinjectorErenumab-Aooe | 26 | $22,027 |
| Emgality PenGalcanezumab-Gnlm | 18 | $16,320 |
| Emgality SyringeGalcanezumab-Gnlm | 18 | $13,028 |
| NayzilamMidazolam | 19 | $12,335 |
| Carbamazepine ErCarbamazepine | 57 | $9,326 |
| Tegretol XrCarbamazepine | 13 | $6,683 |
| Primidone | 163 | $5,348 |
| Oxcarbazepine | 50 | $5,308 |
| Clobazam | 37 | $5,023 |
| Lamotrigine ErLamotrigine | 15 | $4,035 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Eisai Inc.Fycompa | $198 | $70,64055 claims |
| UCB, Inc.Briviact, Nayzilam | $227 | $61,72141 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 361 neurology providers in Tennessee.
Other neurology in Arlington
- Samuel HunterSpring Hill$676K
- Harold MosesNashville$438K
- Lucas ElijovichMemphis$415K
- David BrandesKnoxville$412K
- Sibyl WrayKnoxville$377K
- Christine HagenAlcoa$371K
- Mark LedouxMemphis$352K
- Christopher PendolaKingsport$344K
- Daniel ClaassenNashville$285K
- Khalid AlsherbiniMemphis$249K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.